Gene · 4595
Papers3,741
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,021 to 1,040 of 3,741
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| How Many Times Can One Go Back to the Drawing Board before the Accurate Diagnosis and Surgical Treatment of Glucagonoma? | Diagnostics (Basel) | 2022 | 35054383 | PubTator, text mining | PubMed |
| Prevalence and Management of Cancer of the Rectal Stump after Total Colectomy and Rectal Sparing in Patients with Familial Polyposis: Results from a Registry-Based Study. | Cancers (Basel) | 2022 | 35053462 | PubTator, text mining | PubMed |
| Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology. | Cancer Treat Rev | 2022 | 35051883 | PubTator, text mining | PubMed |
| Colorectal adenocarcinoma with enteroblastic differentiation: diagnostic challenges of a rare case encountered in clinical practice. | J Pathol Transl Med | 2022 | 35051325 | PubTator, text mining | PubMed |
| Comparison of somatic mutation landscapes in Chinese versus European breast cancer patients. | HGG Adv | 2022 | 35047861 | PubTator, text mining | PubMed |
| Characteristics and experiences of patients from a community-based and consumer-directed hereditary cancer population screening initiative. | HGG Adv | 2022 | 35047846 | PubTator, text mining | PubMed |
| Racial and ethnic variation in multigene panel testing in a cohort of BRCA1/2-negative individuals who had genetic testing in a large urban comprehensive cancer center. | Cancer Med | 2022 | 35040284 | PubTator, text mining | PubMed |
| Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation. | Cancer Res Treat | 2022 | 35038823 | PubTator, text mining | PubMed |
| Incidental germline findings during molecular profiling of tumor tissues for precision oncology: molecular survey and methodological obstacles. | J Transl Med | 2022 | 35033101 | PubTator, text mining | PubMed |
| The repertoire of germline variants in patients with early-onset rectal cancer. | Cancer Commun (Lond) | 2022 | 35029067 | PubTator, text mining | PubMed |
| Comprehensive characterization of CRC with germline mutations reveals a distinct somatic mutational landscape and elevated cancer risk in the Chinese population. | Cancer Biol Med | 2022 | 35014770 | PubTator, text mining | PubMed |
| BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients. | Cancers (Basel) | 2022 | 35008403 | PubTator, text mining | PubMed |
| Clinicopathological and genetic study of a rare occurrence: Malignant transformation of fibrous dysplasia of the jaws. | Mol Genet Genomic Med | 2022 | 34989160 | PubTator, text mining | PubMed |
| COL17A1 germline variant p.Ser1029Ala and mucosal malignant melanoma: An autopsy study. | Mol Clin Oncol | 2022 | 34987801 | PubTator, text mining | PubMed |
| Multilocus Inherited Neoplasia Allele Syndrome (MINAS): an update. | Eur J Hum Genet | 2022 | 34983940 | PubTator, text mining | PubMed |
| Monoallelic MUTYH pathogenic variants ascertained via multi-gene hereditary cancer panels are not associated with colorectal, endometrial, or breast cancer. | Fam Cancer | 2022 | 34981295 | PubTator, text mining | PubMed |
| Phosphoserine phosphatase as a prognostic biomarker in patients with gastric cancer and its potential association with immune cells. | BMC Gastroenterol | 2022 | 34979926 | PubTator, text mining | PubMed |
| Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. | Eur Urol | 2022 | 34953602 | PubTator, text mining | PubMed |
| Ovarian cancer ascites induces skeletal muscle wasting in vitro and reflects sarcopenia in patients. | J Cachexia Sarcopenia Muscle | 2022 | 34951138 | PubTator, text mining | PubMed |
RNA-binding proteins and post-transcriptional regulation in lens biology and cataract: Mediating spatiotemporal expression of key factors that control the cell cycle, transcription, cytoskeleton and transparency. | Exp Eye Res | 2022 | 34906599 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4595/papers?page=52